These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. Dowell JE; Minna JD Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125 [No Abstract] [Full Text] [Related]
11. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T; Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748 [TBL] [Abstract][Full Text] [Related]
12. Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer. Hata A; Masago K; Katakami N; Imai Y; Yatabe Y J Thorac Oncol; 2014 Aug; 9(8):e64-5. PubMed ID: 25157783 [No Abstract] [Full Text] [Related]
13. Her2-neu: a target in lung cancer? Andre F; Le Chevalier T; Soria JC Ann Oncol; 2004 Jan; 15(1):3-4. PubMed ID: 14679110 [No Abstract] [Full Text] [Related]
14. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer. Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530 [No Abstract] [Full Text] [Related]
15. Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction. Jänne PA J Clin Oncol; 2006 Jul; 24(21):3319-21. PubMed ID: 16785470 [No Abstract] [Full Text] [Related]